The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

India’s largest drugmaker plans a $100 million push into US specialty drugs in FY26, even as it braces for regulatory ...

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%. The deal strengthens Sun’s ...

Dystrophic epidermolysis bullosa (DEB) is one of the main subtypes of epidermolysis bullosa, a group of genetic skin disorders characterized by varying degrees of fragility in the skin and mucous ...

Macquarie has reaffirmed its ‘outperform’ rating on Sun Pharmaceutical Industries Ltd. and raised its target price to Rs ...

Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, today announced the appointment of Everett E. Vokes, M.D., to its ...

As per Bloomberg estimates, Sun Pharma's consolidated revenue for the March quarter is expected to rise 12.9% year-on-year to ...

Clear signs of immune activation: ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune ...